ARENA PHARMACEUTICALS INC Form 8-K July 19, 2005

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

# FORM 8-K

**Current Report** 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 19, 2005

# Arena Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

000-31161

23-2908305

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# 23-2908305

Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

## 6166 Nancy Ridge Drive, San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)

#### (858) 453-7200

(Registrant s telephone number, including area code)

#### N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

# Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

## Item 2.02. Results of Operations and Financial Condition.

On July 19, 2005, Arena Pharmaceuticals, Inc. issued a press release announcing its financial results for the second quarter and six months ended June 30, 2005. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

#### Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press release issued July 19, 2005, announcing financial results for the second quarter and six months ended June 30, 2005.

# Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 19, 2005

Arena Pharmaceuticals, Inc., a Delaware corporation

/s/ Jack Lief Jack Lief President & Chief Executive Officer

2

By:

# Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

## EXHIBIT INDEX

Exhibit No.

99.1 Press release issued July 19, 2005, announcing financial results for the second quarter and six months ended June 30, 2005.

Description

3